GLP-1

J.P. Morgan says the GLP-1 market across China, India and Brazil could grow to $22 billion by 2035 as cheaper generics widen access to weight-loss drugs.

A major Lancet Psychiatry study of 95,000 people found semaglutide linked to 42% lower risk of worsening depression and anxiety. Here is what it means.